Page 30 - Read Online

Kosmas et al. Vessel Plus 2019;3:2 I http://dx.doi.org/10.20517/2574-1209.2018.79 Page 7 of 7

and atherosclerosis. N Engl J Med 2011;364:127-35.
38. Ogura M, Hori M, Harada-Shiba M. Association between cholesterol efflux capacity and atherosclerotic cardiovascular disease in
patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2016;36:181-8.
39. Huang Y, DiDonato JA, Levison BS, Schmitt D, Li L, et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med
2014;20:193-203.
40. Carnuta MG, Stancu CS, Toma L, Sanda GM, Niculescu LS, et al. Dysfunctional high-density lipoproteins have distinct composition,
diminished anti-inflammatory potential and discriminate acute coronary syndrome from stable coronary artery disease patients. Sci Rep
2017;7:7295.
41. Kratzer A, Giral H, Landmesser U. High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with
coronary artery disease. Cardiovasc Res 2014;103:350-61.
42. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating
pathways in patients with coronary artery disease. J Clin Invest 2011;121:2693-708.
43. Angeloni E, Paneni F, Landmesser U, Benedetto U, Melina G, et al. Lack of protective role of HDL-C in patients with coronary artery
disease undergoing elective coronary artery bypass grafting. Eur Heart J 2013;34:3557-62.
44. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, et al. Association between change in high density lipoprotein cholesterol
and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338:b92.